PMID- 18071824
OWN - NLM
STAT- MEDLINE
DCOM- 20080313
LR  - 20080215
IS  - 1534-4681 (Electronic)
IS  - 1068-9265 (Linking)
VI  - 15
IP  - 2
DP  - 2008 Feb
TI  - Fluorescence in situ hybridization and immunohistochemical analysis of p53 
      expression in endometrial cancer: prognostic value and relation to ploidy.
PG  - 484-92
AB  - BACKGROUND: Endometrial carcinoma is the most common gynecological malignancy. 
      Several molecular biological characteristics have been studied for their 
      potential value in patient management. OBJECTIVES: Our objectives were to compare 
      p53 immunohistochemical expression with P53 gene status determined by 
      fluorescence in situ hybridization (FISH) and to compare these characteristics 
      with ploidy and with classical clinical and histological prognostic factors. 
      MATERIALS AND METHODS: We reviewed stored specimens from 43 patients with 
      endometrial cancer diagnosed in 1999-2004. P53 FISH and immunohistochemistry were 
      performed, together with imaging cytometry to calculate DNA ploidy. RESULTS: 
      Thirteen of the 43 endometrial carcinomas (30.2%) showed P53 loss of 
      heterozygosity (LOH). P53 LOH correlated with the histological type (P = .03) and 
      the histological grade (P = .004). Quantitative immunohistochemical expression of 
      p53 protein correlated with the histological type (P = .0001). With a cutoff of 
      10% of p53-positive cells, p53 overexpression correlated with the histological 
      type (P = .003) and grade (P = .0008). No relation was found between P53 LOH or 
      immunohistochemical expression and the disease stage, the depth of myometrial 
      invasion, lymph node status, lymphovascular space involvement, recurrence, or 
      death from cancer. Nondiploid carcinomas showed deeper myometrial invasion than 
      diploid carcinomas (P = .01). No relation was observed between ploidy and 
      qualitative or semiquantitative p53 expression or P53 LOH. CONCLUSION: In 
      endometrial cancer, FISH analysis of P53 status adds no significant prognostic 
      information compared with immunohistochemical p53 analysis.
FAU - Graesslin, Olivier
AU  - Graesslin O
AD  - Service de Cytogenetique, Hopital Tenon, AP-HP, F-75020 Paris, France. 
      ograesslin@chu-reims.fr
FAU - Chantot-Bastaraud, Sandra
AU  - Chantot-Bastaraud S
FAU - Lorenzato, Marianne
AU  - Lorenzato M
FAU - Birembaut, Philippe
AU  - Birembaut P
FAU - Quereux, Christian
AU  - Quereux C
FAU - Darai, Emile
AU  - Darai E
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20071211
PL  - United States
TA  - Ann Surg Oncol
JT  - Annals of surgical oncology
JID - 9420840
RN  - 0 (Tumor Suppressor Protein p53)
SB  - IM
MH  - Endometrial Neoplasms/*genetics/*metabolism/pathology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - *In Situ Hybridization, Fluorescence
MH  - Loss of Heterozygosity
MH  - Myometrium/pathology
MH  - Neoplasm Invasiveness
MH  - Ploidies
MH  - Prognosis
MH  - Tumor Suppressor Protein p53/*metabolism
EDAT- 2007/12/12 09:00
MHDA- 2008/03/14 09:00
CRDT- 2007/12/12 09:00
PHST- 2007/05/20 00:00 [received]
PHST- 2007/10/23 00:00 [accepted]
PHST- 2007/10/19 00:00 [revised]
PHST- 2007/12/12 09:00 [pubmed]
PHST- 2008/03/14 09:00 [medline]
PHST- 2007/12/12 09:00 [entrez]
AID - 10.1245/s10434-007-9712-1 [doi]
PST - ppublish
SO  - Ann Surg Oncol. 2008 Feb;15(2):484-92. doi: 10.1245/s10434-007-9712-1. Epub 2007 
      Dec 11.